What is Kailera Therapeutics
's deferred offering costs included in accounts payable and accrued expenses?

Name: Kailera Therapeutics Deferred Offering Costs Included In Accounts Payable And Accrued Expenses — Quarterly & Annual Data
Creator: OpenCapital
License: https://www.opencapital.sh/terms

Question

Accepted Answer

Kailera Therapeutics
 (KLRA) reported deferred offering costs included in accounts payable and accrued expenses of $2.12M in Q1 2026.

Deferred Offering Costs Included In Accounts Payable And Accrued Expenses

Analysis

Historical Data

Frequently Asked Questions